They are classified as glucagon-like peptide 1 (GLP-1) agonists and, in addition to diabetes treatment, also demonstrate ...

Later-to-market Ozempic is lagging behind Trulicity, with first-half sales of around $550 million, but has been predicted to reach $2 to $3 billion per year at peak, with Rybelsus having the ...

The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus, a key pipeline drug in its type 2 diabetes franchise. Rybelsus (semaglutide) is the first GLP-1 ...

Rybelsus (semaglutide) is a brand-name prescription medication that doctors prescribe alongside exercise and diet to help improve blood sugar levels in adults with type 2 diabetes. Plans often ...